Ecovia Bio raises Series B funding led by Pointe Angels to expand ?-PGA manufacturing and replace microplastic-forming polymers globally.
Ecovia Bio, an innovative biotechnology company focused on the development of sustainable, high-performance biopolymer solutions, has successfully closed its Series B funding round. The investment was led by Pointe Angels, a prominent independent angel investor network headquartered in the Grosse Pointe communities near Detroit, Michigan. This latest infusion of capital marks a significant milestone for Ecovia Bio and will be primarily used to substantially expand manufacturing capabilities at the company’s advanced production facility in Livonia, Michigan.
The expanded capacity is aimed at meeting rapidly increasing global demand for Ecovia Bio’s proprietary AzuraBase® and AzuraGel® product lines. These offerings are based on gamma polyglutamic acid (γ-PGA), a next-generation, bio-based polymer known for its exceptional performance and complete biodegradability. Ecovia Bio’s γ-PGA solutions are gaining strong traction across multiple end-use markets, including cosmetics, personal care, agriculture, hygiene products, and other consumer and industrial applications that traditionally rely on petrochemical-derived polymers.
The funding announcement comes at a time when environmental sustainability and human health concerns are reshaping material choices across industries worldwide. Microplastics have become a critical global issue, with mounting scientific evidence highlighting their persistence in ecosystems and their infiltration into the human body. Conventional superabsorbent polymers (SAPs), which are widely used in products such as diapers, feminine hygiene items, lotions, and cosmetics, are largely synthesized from fossil-based feedstocks. These materials do not readily degrade and can remain in landfills for hundreds of years, slowly breaking down into microplastics that contaminate soil, freshwater systems, oceans, and the food supply.
Alarmingly, researchers have detected microplastics in human bloodstreams, lung tissue, and even placental samples, intensifying concerns about their long-term health implications. Against this backdrop, Ecovia Bio’s γ-PGA technology offers a compelling alternative. Derived through advanced biotechnology processes, γ-PGA is fully biodegradable, non-toxic, and bio-based, while delivering performance characteristics that meet or exceed those of traditional synthetic polymers.
By scaling up γ-PGA production, Ecovia Bio aims to help manufacturers eliminate persistent plastics from everyday products without compromising quality, functionality, or consumer experience. The company’s solutions enable brands to respond effectively to tightening regulations, increasing scrutiny from regulators, and growing consumer demand for safer, environmentally responsible products. At the same time, these innovations support broader efforts to reduce reliance on petrochemicals and mitigate the long-term ecological and health risks associated with plastic pollution.
The Series B funding will also support Ecovia Bio’s long-term growth strategy, including the development of a roadmap for additional manufacturing sites beyond Livonia. By expanding its production footprint and strengthening supply reliability, the company is positioning itself as a dependable global partner for brands seeking sustainable material alternatives at commercial scale.
Through continued investment in biotechnology, manufacturing excellence, and strategic partnerships, Ecovia Bio is working toward its vision of becoming a leading global supplier of γ-PGA and specialty biopolymers. The company’s progress underscores the growing role of bio-based materials in enabling a transition toward more sustainable, circular, and health-conscious consumer and industrial products worldwide.
